Regulus Therapeutics is developing treatments for renal, hepatic and central nervous systems diseases based on microRNA targeting.
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
| Website: | www.regulusrx.com |
| Email: | information@regulusrx.com |
| Main Phone: | +1 858 202-6300 |
| Address: | 10628 Science Center Drive |
| Address 2: | Suite 225 |
| State: | CA |
| City / Town: | San Diego |
| Country: | US |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Joseph P. Hagan |
| Employees: | 24 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Regulus Therapeutics is developing treatments for renal, hepatic and central nervous systems diseases based on microRNA targeting.
A biotech analyst could play it safe, and stick with mid-, late- and commercial-stage companies that offer higher odds and decent returns on good news. Christopher James, on the other hand,
Small-cap companies (that is, companies that are worth between $300 million and $2 billion) can be a risky investment, as smaller companies tend to have lower stock prices and thus are more
Futures Outlook for the Week: 02/4/13This week we are going to cover three C’s: Cocoa, Coffee, and Copper. The first two may be in the market for some counter trend plays and the last of them
LifeLock Inc. (LOCK) began trading as a public company this morning with an initial public offering of 15.7 million shares at $9 each. The $9 per share price tag is below the original price range
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
